

Bone Medical


ASX/MEDIA RELEASE

Results of General Meeting

3 October 2012: Bone Medical Limited (ASX: BNE) advises, in relation to the General Meeting held yesterday and in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, details of the resolutions and proxies received. The Chairman voted in favour of the resolution where allowed for by those open proxies provided for his discretion.

No.	Detail	For	Against	Open	Abstain
1	Approval of issue of Shares to professional and sophisticated investors	3,373,094	4,750	106,492,677	1,041
2	Ratification of previous issue of Shares to La Jolla Cove Investors (La Jolla)	3,372,094	5,750	106,492,677	1,041
3	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
4	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
5	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
6	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
7	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
8	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
9	Ratification of previous issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041
10	Approval of issue of Shares to La Jolla	3,372,094	5,750	106,492,677	1,041

All resolutions were passed by a show of hands.



Bone Medical

- ENDS -

Enquiries:

Dr Roger New

Chairman

Office: +44 207 794 1512

Leon Ivory

Director

Mobile: +61 419 428 264

or visit: www.bonemedical.com

Peter Young

CEO

Mobile: +1 201 841 9681

About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical company focused on developing significant new products for the growing market in the treatment of bone diseases like osteoarthritis, rheumatoid arthritis, and osteoporosis. The Company's product pipeline includes:

- Phase II clinical-stage programs for the oral delivery of two well-established peptides which have historically been limited to nasal or injectable delivery
 - CaPTHymone™ (oral parathyroid hormone) for osteoporosis
 - Capsitonin™ (oral calcitonin)
 - Osteoarthritis pain
 - Osteoporosis
- Novel, potential breakthrough preclinical-stage compounds
 - BN006 – selective, potential oral TNF-alpha inhibitor for rheumatoid arthritis (RA)
 - BN007 – collagen tolerance & joint protection agent for RA
 - BN005 & BN008 – bone cell regulation for osteoporosis